Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on April 1, 2015. The filing reports a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors unanimously voted to increase its size to seven members.
- New Director: Jeffrey Capello was elected to the Board, effective immediately, as a Class III member serving until the 2018 annual meeting.
- Committee Role: Mr. Capello was elected as the Chairman of the Audit Committee.
- Compensation: Mr. Capello will receive compensation consistent with other non-employee directors, as detailed in the Company's final prospectus dated January 28, 2015.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It notes that Mr. Capello entered into the Company's standard Indemnity Agreement.
Investor Verification Checklist
- Verify the correct registrant name is Flex Pharma, Inc., not Decoy Therapeutics Inc.
- Review the final prospectus dated January 28, 2015, for details on director cash compensation.
- Confirm the terms of the standard Indemnity Agreement filed as Exhibit 10.1 to Amendment No. 1 to the Registration Statement on Form S-1.
- Check subsequent filings for any financial updates, as this 8-K contains no financial data.